ADAP Form 3 — CFO Christopher Hill Reports Zero Ownership

Rhea-AI Filing Summary

Christopher James Hill, identified as Chief Financial Officer and a director of Adaptimmune Therapeutics PLC (ADAP), filed an Initial Form 3 reporting that he does not beneficially own any securities of the issuer as of the event date 09/10/2025. The filing is signed 10/08/2025 and lists the reporter's business address in Abingdon, UK. No non-derivative or derivative holdings are disclosed on the form.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Hill Christopher James

(Last) (First) (Middle)

C/O ADAPTIMMUNE THERAPEUTICS PLC

60 JUBILEE AVENUE, MILTON PARK

(Street)

ABINGDON X0 OX14 4RX

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
09/10/2025

3. Issuer Name and Ticker or Trading Symbol
Adaptimmune Therapeutics PLC [ ADAP ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Christopher James Hill	10/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Adaptimmune (ADAP) Form 3 filed by Christopher James Hill report?

The Form 3 states that Christopher James Hill, the company's Chief Financial Officer and director, does not beneficially own any securities of Adaptimmune as of 09/10/2025.

When was the Form 3 signed for the ADAP reporting by Christopher James Hill?

The Form 3 bears the reporting person's signature dated 10/08/2025.

Does the Form 3 list any stock options, warrants, or other derivative holdings for ADAP by the reporting person?

No. Table I and Table II contain no entries and the form includes the explicit explanation: 'No securities are beneficially owned.'

What role does Christopher James Hill hold at Adaptimmune (ADAP)?

He is listed as a Director and the company's Chief Financial Officer on the Form 3.